Intellia Therapeutics Inc (NASDAQ:NTLA)’s traded shares stood at 0.49 million during the latest session, with the company’s beta value hitting 2.13. At the last check today, the stock’s price was $9.18, to imply a decrease of -1.29% or -$0.12 in intraday trading. The NTLA share’s 52-week high remains $28.54, putting it -210.89% down since that peak but still an impressive 9.59% since price per share fell to its 52-week low of $8.30. The company has a valuation of $950.29M, with an average of 2.85 million shares in intraday trading volume over the past 10 days and average of 3.14 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Intellia Therapeutics Inc (NTLA), translating to a mean rating of 1.69. Of 13 analyst(s) looking at the stock, 0 analyst(s) give NTLA a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 13 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.26.
Intellia Therapeutics Inc (NASDAQ:NTLA) trade information
After registering a -1.29% downside in the latest session, Intellia Therapeutics Inc (NTLA) has traded red over the past five days. The 5-day price performance for the stock is -0.43%, and -25.24% over 30 days. With these gigs, the year-to-date price performance is -21.27%. Short interest in Intellia Therapeutics Inc (NASDAQ:NTLA) saw shorts transact 26.04 million shares and set a 7.91 days time to cover.
The extremes give us $9 and $60 for target low and target high price respectively. As such, NTLA has been trading -553.59% off suggested target high and 1.96% from its likely low.
Intellia Therapeutics Inc (NTLA) estimates and forecasts
The rating firms project that company’s revenue will shrink -17.91% compared to the previous financial year.
Revenue forecast for the current quarter as set by 20 analysts is 11.39M. Meanwhile, for the current quarter, a total of 20 analyst(s) estimate revenue growth to 11.37M.Earnings reports from the last fiscal year show that sales brought in 28.93M and 6.96M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -60.65% before jumping 63.41% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -20.04% for the past 5-year period. While 2025 is set for a 11.04% return in earnings, projections for the next 5 years are at 25.47% annually.
NTLA Dividends
Intellia Therapeutics Inc has its next earnings report out on 2025-Feb-26. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Intellia Therapeutics Inc (NASDAQ:NTLA)’s Major holders
Intellia Therapeutics Inc insiders hold 5.05% of total outstanding shares, with institutional holders owning 91.72% of the shares at 96.60% float percentage. In total, 91.72% institutions holds shares in the company, led by ARK INVESTMENT MANAGEMENT LLC. As of 2024-06-30, the company held over 11.6 million shares (or 11.9575% of shares), all amounting to roughly $259.51 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 9.6 million shares, or about 10.0496% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $214.79 million.
We also have ARK Innovation ETF and ARK Genomic Revolution ETF as the top two Mutual Funds with the largest holdings of the Intellia Therapeutics Inc (NTLA) shares. Going by data provided on Feb 28, 2025 , ARK Innovation ETF holds roughly 8.72 shares. This is just over 8.42% of the total shares, with a market valuation of $79.6 million. Data from the same date shows that the other fund manager holds a little less at 3.09, or 2.98% of the shares, all valued at about 28.17 million.
